Core Insights - The Chinese quick-freezing machine industry is at a critical juncture of opportunities and challenges, characterized by strong demand growth and accelerated technological upgrades. The market size is projected to reach approximately 3.946 billion yuan in 2024, representing a year-on-year growth of 10.35% [1][8]. Industry Overview - Quick-freezing machines, also known as freezing equipment, are industrial refrigeration devices primarily used for rapid freezing of food products. They function by using refrigeration systems and air circulation to lower the center temperature of items to below -18°C within 30 minutes, minimizing nutrient loss [2][4]. - The industry includes various types of quick-freezing machines, such as tunnel freezers, spiral freezers, fluidized freezers, and liquid nitrogen freezers [3]. Market Size - The growth in the quick-freezing machine market is driven by multiple demand engines, including the explosive growth of the prepared food industry, which increases the demand for high-end equipment like liquid nitrogen and spiral freezers. Additionally, the biopharmaceutical sector's requirements for ultra-low temperature storage and frost-free technology, along with the expansion of cold chain logistics, are contributing to the demand [1][7][8]. Industry Chain - The upstream of the quick-freezing machine industry includes raw materials and components such as steel, stainless steel, compressors, evaporators, fans, sensors, control systems, and environmentally friendly refrigerants. The midstream involves the manufacturing of quick-freezing machines, while the downstream applications span food processing, biopharmaceuticals, chemicals, and electronics [4]. Key Companies - The competitive landscape of the quick-freezing machine industry is characterized by leading companies such as Ice Wheel Environment, which offers a full-service capability from core compressors to large-scale spiral and tunnel freezing production lines. Ice Mountain Cold is also a key player with advanced technology in industrial refrigeration and commercial cold chain sectors [8][9][11]. Industry Development Trends 1. **Technological Innovation**: The focus is shifting from merely preserving food to enhancing its quality through advanced freezing technologies, such as the "cloud freezing" technology that minimizes cell damage and juice loss [13]. 2. **Customized Solutions**: The rapid growth of the prepared food industry is driving the need for diverse and refined equipment solutions, requiring quick-freezing machines to adapt to various food types and freezing requirements [14]. 3. **Smart and Green Development**: The industry's future will revolve around smart technologies and sustainability, integrating IoT, AI, and energy-efficient practices to enhance operational efficiency and reduce environmental impact [15].

Core Findings - The research indicates a significant positive correlation between good ESG practices and corporate brand value, with the environmental (E) and governance (G) dimensions having a more pronounced positive impact [2][9] - Under the "dual carbon" goals, companies' green production and energy-saving performance are more likely to gain international recognition, while governance structure optimization enhances market trust [2][3] - The social (S) dimension's impact on brand value is relatively weaker due to differences in standards between China and the West [2][3] ESG Practices and Corporate Governance - Leading companies typically adopt an embedded governance model for ESG, integrating it into strategic planning, product innovation, and supply chain management [2][3] - Hikvision has established a dual-axis governance structure, Huabao New Energy has developed a green factory system, BYD links ESG performance to executive compensation, and Haier Biomedical achieves a blend of commercial and social value through technological innovation [2][3] - These companies reflect a shift from "compliance-oriented" to "value-driven" ESG practices, aligning with international technical standards while retaining local characteristics [2][3] Challenges and Recommendations - Current challenges include non-unified ESG information disclosure standards, insufficient transformation capabilities of small and medium-sized enterprises, and the need for improved international discourse adaptability [3] - Recommendations include embedding ESG deeply into governance structures, constructing localized narrative systems, and enhancing industry chain collaboration [3] - The government should improve a tiered and categorized ESG standard system and establish diverse incentive mechanisms and public service platforms [3] Importance of ESG in Global Competitiveness - ESG has become a core indicator of corporate international competitiveness amid the global sustainable development agenda [3] - Chinese international enterprises need to implement systematic ESG practices to balance international standards with local adaptation, using environmental innovation as a breakthrough point to enhance brand value and international influence [3]

证券日报网讯2月3日，海尔生物在互动平台回答投资者提问时表示，截至2026年1月31日，公司股东总 数为14209户。 ...

资料显示，青岛海尔生物医疗股份有限公司位于山东省青岛市高新区丰源路280号海尔生物医疗新兴产 业园，成立日期2005年10月28日，上市日期2019年10月25日，公司主营业务涉及生物医疗低温存储设备 的研发、生产和销售。主营业务收入构成为：医疗器械及相关产品98.81%，安装收入0.74%，软件维护 服务收入0.42%，租赁收入0.02%。 截至1月20日，海尔生物股东户数1.40万，较上期增加5.33%；人均流通股22571股，较上期减少5.06%。 2025年1月-9月，海尔生物实现营业收入17.61亿元，同比减少1.17%；归母净利润1.98亿元，同比减少 35.83%。 2月2日，海尔生物跌3.42%，成交额1.13亿元。两融数据显示，当日海尔生物获融资买入额1721.44万 元，融资偿还2360.88万元，融资净买入-639.44万元。截至2月2日，海尔生物融资融券余额合计2.47亿 元。 融资方面，海尔生物当日融资买入1721.44万元。当前融资余额2.45亿元，占流通市值的2.41%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，海尔生物2月2日融券偿还2300.00股，融券卖出 ...

经上海证券交易所科创板股票上市委员会2019年7月30日审核同意，并经中国证券监督管理委员会2019 年9月20日下发《关于同意青岛海尔生物医疗股份有限公司首次公开发行股票注册的批复》（证监许可 [2019]1742号）核准，同意海尔生物公开发行人民币普通股不超过79,267,940股，每股发行价格为人民 币15.53元，募集资金总额为人民币1,231,031,108.20元，实际到账金额人民币1,161,576,074.14元，包括 尚未划转的其他发行费用。上述募集资金于2019年10月22日到位，并经安永华明会计师事务所（特殊普 通合伙）审验并出具了安永华明（2019）验字第61433766_J04号验资报告。主承销商为国泰君安证券股 份有限公司司（现名"国泰海通证券股份有限公司"）。 (责任编辑：马欣) 中国经济网北京2月2日讯 海尔生物(688139.SH)近日发布公告称，公司近日收到青岛海创睿股权投资基 金中心（有限合伙）（以下简称"海创睿"）出具的《关于股份减持计划的告知函》。因自身资金需求， 海创睿拟通过集中竞价方式减持海尔生物股份，减持股份占海尔生物总股本的比例不超过0.85%，即不 超过2, ...

证券代码：688139 证券简称：海尔生物 公告编号：2026-005 青岛海尔生物医疗股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 股东持股基本情况 2.为严格履行公司回购股份方案中关于回购股份使用期限的相关承诺，同时增强投资者回报能力和水平， 切实维护广大投资者利益，公司将第一次回购计划存放于回购专用账户中的 1,459,586 股已回购股份用途 由"用于员工持股计划或股权激励"变更为"用于注销并相应减少注册资本"并已于 2026 年 1 月 6 日注销 完成。 2 青岛海创睿股权投资基金中心（有限合伙）（以下简称"海创睿"）持有青 岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）32,103,659 股，占公司总股本的 10.14%。该股份属于公司首次公开发行前取得的股份，截 至本公告披露日，上述股东所持股份均已上市流通。 海创睿与公司实际控制人海尔集团公司（以下简称"海尔集团"）签署了《表 决权委托协议》，构成一致行动关系。此外，海尔 ...

Core Viewpoint - Haier Bio received a notice from Haichuang Rui regarding a share reduction plan due to its own funding needs, indicating a potential impact on the company's stock performance [1] Group 1: Share Reduction Plan - Haichuang Rui plans to reduce its shareholding in Haier Bio through centralized bidding, with a maximum reduction of 0.85% of the total share capital, equivalent to no more than 2,690,189 shares [1] - The reduction period is set to begin 15 trading days after the announcement of this reduction plan and will last for three months [1] - The reduction price will be determined based on market prices [1]

证券代码：688139 证券简称：海尔生物 公告编号：2026-005 青岛海尔生物医疗股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 股东持股基本情况 青岛海创睿股权投资基金中心（有限合伙）（以下简称"海创睿"）持有青 岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）32,103,659 股，占公司总股本的 10.14%。该股份属于公司首次公开发行前取得的股份，截 至本公告披露日，上述股东所持股份均已上市流通。 海创睿与公司实际控制人海尔集团公司（以下简称"海尔集团"）签署了《表 决权委托协议》，构成一致行动关系。此外，海尔集团还通过其控制的青岛海尔 生物医疗控股有限公司（以下简称"海尔生物医疗控股"）以及一致行动人青岛 海创智管理咨询企业（有限合伙）（以下简称"海创智"）分别持有公司股份 100,591,463 股和 8,675,900 股，占公司总股本的 31.78%、2.74%。 海尔集团一致行动人海创智分别于 2022 年 3 月、2 ...

海尔生物公告，持股10.14%的股东青岛海创睿股权投资基金中心（有限合伙）因资金需求，拟通过集 中竞价方式减持不超过269.02万股，占公司总股本0.85%，期限为2026年3月3日至2026年6月2日；其现 持有3210.37万股，均为IPO前取得股份。截至公告披露日，实际控制人及一致行动人合计持股1.41亿 股，占44.67%，自上市以来未减持公司股份，减持计划不会导致控制权变更。 ...

Core Viewpoint - Haier Biomedical aims to become a world-class brand in life sciences trusted by global users, with a focus on expanding its business internationally and enhancing its industry presence [1] Group 1: Business Expansion - The company has expanded its operations to over 150 countries and regions worldwide [1] - Localized deployments have been established in 18 countries [1] - Revenue from overseas markets now accounts for more than 35% of total income [1] Group 2: Strategic Focus - Haier Biomedical is committed to a strategy of both organic growth and external acquisitions within the life sciences sector [1] - The company plans to identify high-quality targets in the life sciences industry to strengthen its existing operations and broaden its business scope [1] - There is an emphasis on entering high-potential market segments [1]